Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
2023-10-19 07:26:46 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche in pact with Monte Rosa to develop cancer and neuro drugs Data shows Genentech's Fenebrutinib redu...
2023-10-17 08:20:15 ET More on Monte Rosa Seeking Alpha’s Quant Rating on Monte Rosa Therapeutics Historical earnings data for Monte Rosa Therapeutics Financial information for Monte Rosa Therapeutics For further details see: Roche in pact with Mon...
2023-10-17 07:30:08 ET More on Gamida Cell Gamida Cell: The Treacherous Path To Profitability Gamida Cell Ltd. (GMDA) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Gamida Cell Historical earnings data for Gamida Cell Financia...
2023-10-13 12:38:42 ET More on Roche Holding Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche's Ocrevus' 10-year data shows MS drug cuts disability progression AbbVie blood cancer therapy fails in Phase 3 trial For further ...
2023-10-13 04:57:44 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Ionis licenses two candidates to Roche for Alzheimer's, Huntington's U.S. govt. to restart program to sh...
2023-10-09 12:37:47 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-09-29 08:18:50 ET More on AbbVie, Roche, etc. Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie attempt to nix IBD drug patent challenge fails ...
2023-09-27 10:25:40 ET More on Ionis Pharmaceuticals, Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Ionis late-stage rare disease data fails t...
2023-09-20 15:26:50 ET More on COVID-19 test makers Compare metrics for ABT to BDX, RHHBF Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income ...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...